|
(1)
|
Title
of each class of securities to which transaction
applies:
|
|
(2)
|
Aggregate
number of securities to which transaction
applies:
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was
determined):
|
|
(4)
|
Proposed
maximum aggregate value of
transaction:
|
|
(5)
|
Total
fee paid:
|
|
(1)
|
Amount
Previously Paid:
|
|
(2)
|
Form,
Schedule or Registration Statement
No.:
|
|
(3)
|
Filing
Party:
|
|
(4)
|
Date
Filed:
|
|
1.
|
The
election of eight directors to serve until the next Annual Meeting of
Stockholders and until their respective successors are elected and
qualified.
|
|
2.
|
The
approval of an amendment to our 1998 Employee Stock Purchase Plan to
increase the number of shares of common stock reserved for issuance
thereunder to 2,400,000 and the amendment to our 1998 Non-Qualified
Employee Stock Purchase Plan to increase the number of shares of common
stock reserved for issuance thereunder to
600,000.
|
|
3.
|
The
ratification of the selection of PricewaterhouseCoopers LLP to serve as
our independent registered public accounting firm for the fiscal year
ending December 31, 2008.
|
|
4.
|
The
transaction of such other business as may properly come before the meeting
and any adjournments thereof.
|
|
Summary Compensation
Table
|
|
Grants of Plan-Based Awards
For Fiscal Year 2007
|
|
Outstanding Equity Awards
at Fiscal Year-End
|
|
Option Exercises and Stock
Vested in Fiscal Year 2007
|
|
Director Compensation in
Fiscal Year 2007
|
|
Narrative for Director
Compensation Table
|
|
Potential Payments Upon
Termination or
Change-in-Control
|
|
Narrative for Potential
Payments Upon Termination or Change-in-Control
Table
|
Name
|
Age
|
Year
First
Elected Director
|
Position
with Company
|
|||||||
Kurt
W. Briner (2)
|
63
|
1998
|
Co-Chairman, Director
|
|||||||
Paul
F. Jacobson (1)(2)(3)
|
54
|
1990
|
Co-Chairman, Director
|
|||||||
Paul
J. Maddon, M.D., Ph.D.
|
48
|
1986
|
Chief Executive Officer,
Chief Science Officer and
Director
|
|||||||
Charles
A. Baker (1)(2)(3)
|
75
|
1994
|
Director
|
|||||||
Mark
F. Dalton (2)(3)
|
57
|
1990
|
Director
|
|||||||
Stephen
P. Goff, Ph.D. (2)
|
56
|
1993
|
Director
|
|||||||
David
A. Scheinberg, M.D., Ph.D.
|
52
|
1996
|
Director
|
|||||||
Nicole
S. Williams (1)
|
63
|
2007
|
Director
|
Share
Value of Grants
|
|||
Name
and Position
|
ESPP
(1)
|
Non-Qualified
ESPP (1)
|
Number
of Shares
|
Paul
J. Maddon, M.D., Ph.D.
|
—
|
$16,729
|
704
|
Chief
Executive Officer, Chief Science Officer and Director (2)
|
|
|
|
Robert
A. McKinney, CPA
|
$
4,831
|
$7,263
|
518
|
Chief
Financial Officer, Senior Vice President Finance & Operations and
Treasurer
|
|||
Mark
R. Baker, J.D.
|
$
4,831
|
$11,442
|
703
|
Senior
Vice President & General Counsel
|
|||
Thomas
A. Boyd, Ph.D.
|
$
4,831
|
$11,176
|
679
|
Senior
Vice President, Product Development
|
|||
Alton
B. Kremer, M.D., Ph.D.
|
$
4,831
|
$13,818
|
790
|
Vice
President, Clinical Research
|
|||
All
current executive officers as a group
|
$28,985
|
$75,
791
|
4,463
|
All
current directors who are not executive officers as a group
(3)
|
—
|
—
|
|
All
employees, including all current officers who are not executive officers,
as a group
|
$4,069,064
|
$992,619
|
219,877
|
(1)
|
The
price range for the ESPP was $16.27 to $23.46 and the price range for the
Non-Qualified ESPP was $17.80 to
$23.46.
|
(2)
|
As
the holder of a beneficial interest in more than 5% of common stock, Dr.
Maddon is not eligible for an option grant under the
ESPP.
|
(3)
|
Directors
of the Company who are not also employees of the Company are not eligible
to participate in the Plans.
|
Category
|
(a)
Number
of shares
to
be issued upon exercise of outstanding options, warrants and
rights
|
(b)
Weighted
average exercise price of outstanding options, warrants and
rights
|
(c)
Number
of shares remaining available for future issuance (excluding securities
reflected in 1st column)
|
|||||||||
Equity
compensation plans approved by stockholders
|
4,577,150
|
(1) |
$
|
18.62
|
2,591,047
|
(2) | ||||||
Equity
compensation plans not approved by stockholders (3)
|
131,218
|
1.44
|
|
— | ||||||||
Total
|
4,708,368
|
$
|
18.14
|
2,591,047 |
(1)
|
Does
not include options issued under the ESPP or the Non-Qualified
ESPP.
|
(2)
|
Includes
473,565 shares available for issuance under the ESPP and 321,240 shares
available for issuance under the Non-Qualified
ESPP.
|
(3)
|
Consists
only of our 1989 Non-Qualified Stock Option Plan (See the Notes to the
Financial Statements included in our Annual Report on Form 10-K for the
year ended December 31,
2007).
|
Type of Fee
|
2007
|
2006
|
||||||
Audit
Fees (1)
|
$ | 592,526 | $ | 656,447 | ||||
Audit
Related Fees (2)
|
- | 39,000 | ||||||
Tax
Fees (3)
|
59,500 | 144,000 | ||||||
All
Other Fees (4)
|
1,611 | 1,611 |
(1)
|
Consisted
of fees billed or expected to be billed by PricewaterhouseCoopers LLP in
connection with (i) the audit of our annual financial statements,
including attestation services required under section 404 of the
Sarbanes-Oxley Act of 2002, and reviews of our quarterly interim financial
statements, totaling $535,026 in 2007 and $646,447 in 2006; (ii) the
filing of registration statements with the Securities and Exchange
Commission, totaling $57,500 in 2007 and $10,000 in 2006.
|
(2)
|
Consisted
of fees billed or expected to be billed by PricewaterhouseCoopers LLP for
accounting advice, including consultations concerning financial accounting
and reporting matters, totaling $39,000 in
2006.
|
(3)
|
Consisted
of fees billed or expected to be billed by PricewaterhouseCoopers LLP for
tax-related services, including tax return preparation and
advice. Fees billed or expected to be billed by
PricewaterhouseCoopers LLP for (i) tax return preparation and other
tax-related services totaling $59,500 in 2007 and $30,000 in 2006; (ii)
tax return preparation for PSMA Development Company LLC total expense to
us of $14,000 in 2006, and (iii) tax advice and consultation, regarding
Internal Revenue Code section 382 analysis of $50,000 in 2006 and $27,500
in 2007, and tax planning totaling $50,000 in 2006 and $32,500 in
2007. PricewaterhouseCoopers LLP has not yet completed its work
on our tax returns for the fiscal year ended December 31,
2007.
|
(4)
|
Consisted
of fees to PricewaterhouseCoopers LLP for a proprietary internet-based
subscription service.
|
Name
|
Age
|
Position
|
Paul
J. Maddon, M.D., Ph.D.
|
48
|
Chief
Executive Officer, Chief Science Officer and Director
|
Robert
A. McKinney, CPA
|
51
|
Chief
Financial Officer, Senior Vice President, Finance & Operations and
Treasurer
|
Mark
R. Baker, J.D.
|
53
|
Senior
Vice President & General Counsel and Secretary
|
Thomas
A. Boyd, Ph.D.
|
56
|
Senior
Vice President, Product Development
|
Robert
J. Israel, M.D.
|
51
|
Senior
Vice President, Medical Affairs
|
Alton
B. Kremer, M.D., Ph.D.
|
55
|
Senior
Vice President, Clinical Research
|
Walter
M. Capone, M.B.A.
|
43
|
Vice
President, Commercial Development and Operations
|
Richard
W. Krawiec, Ph.D.
|
60
|
Vice
President, Corporate Affairs
|
William
C. Olson, Ph.D.
|
45
|
Vice
President, Research & Development
|
Benedict
Osorio, M.B.A.
|
51
|
Vice
President, Quality
|
Nitya
G. Ray, Ph.D.
|
55
|
Vice
President, Manufacturing
|
·
|
Attract
and retain those executives critical to our overall
success;
|
·
|
Reward
executives for their contributions to the achievement of our strategic
goals which we believe will enhance stockholder
value;
|
·
|
Maintain
and continue to foster a company culture of ownership, creativity and
innovation; and
|
·
|
Motivate
our NEOs to achieve the critical financial, product and development
milestones (both long- and short-term) set by management and the
Board.
|
Adolor
Corporation
|
BioMarin
Pharmaceutical Inc.
|
Cell
Therapeutics, Inc.
|
CV
Therapeutics, Inc.
|
Cytokinetics,
Inc.
|
Dendreon
Corporation
|
Immunomedics,
Inc.
|
Indevus
Pharmaceuticals, Inc.
|
Medarex,
Inc.
|
Regeneron
Pharmaceuticals, Inc.
|
SuperGen,
Inc.
|
Theravance,
Inc.
|
Vical
Inccorporated
|
Trimeris,
Inc.
|
Alexion
Pharmaceuticals, Inc.
|
Myriad
Genetics, Inc.
|
Exelixis
Inc.
|
Neurocrine
Biosciences, Inc.
|
Human
Genome Sciences, Inc.
|
Nuvelo,
Inc.
|
Idenix
Pharmaceuticals, Inc.
|
Regeneron
Pharmaceuticals, Inc.
|
Intermune,
Inc.
|
Telik,
Inc.
|
Medarex,
Inc.
|
Theravance,
Inc.
|
·
|
base
salary;
|
·
|
annual
bonus;
|
·
|
long-term
incentives; and
|
·
|
retirement
and severance benefits.
|
Name and Principal Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Stock
Awards1
($)
|
Option
Awards2
($)
|
All
Other Compen-
sation3
($)
|
Total
($)
|
Paul
J. Maddon, M.D., Ph.D.
|
2007
|
600,000
|
491,3124
|
640,561
|
1,768,883
|
16,806
|
3,517,562
|
Chief
Executive Officer
|
2006
|
565,000
|
401,5774
|
785,883
|
2,835,272
|
16,306
|
4,604,038
|
Robert
A. McKinney, CPA
|
2007
|
270,000
|
110,0005
|
143,762
|
339,904
|
25,923
|
889,589
|
Chief
Financial Officer
|
2006
|
250,000
|
100,0005
|
80,607
|
318,469
|
25,423
|
774,499
|
Senior
Vice President,
|
|||||||
Finance
& Operations
|
|||||||
Mark
R. Baker, J.D.
|
2007
|
325,000
|
200,0005
|
88,185
|
632,094
|
20,500
|
1,265,779
|
Senior
Vice President &
|
2006
|
300,000
|
200,0005
|
24,949
|
504,011
|
20,000
|
1,048,960
|
General
Counsel
|
|||||||
Thomas
A. Boyd, Ph.D.
|
2007
|
270,000
|
220,0005,6
|
170,252
|
337,351
|
26,161
|
1,063,764
|
Senior
Vice President,
|
2006
|
250,000
|
125,0005
|
165,817
|
476,864
|
25,516
|
1,043,197
|
Product
Development
|
|||||||
Alton
B. Kremer, M.D., Ph.D.
|
2007
|
380,000
|
245,0005,6
|
129,012
|
363,675
|
26,472
|
1,144,159
|
Senior
Vice President,
|
2006
|
340,000
|
125,0005
|
112,833
|
280,894
|
26,257
|
884,984
|
Clinical
Research
|
(1)
|
The
amounts shown in this column represent the amount of compensation accrued
for each NEO during the fiscal year under FAS 123R. The amounts
do not represent the grant date fair value of equity compensation granted
in fiscal year 2007. The grant date fair value of the awards
granted in 2007 is shown in the Grant of Plan Based Awards For Fiscal Year
2007 table, below.
|
(2)
|
The
amounts shown in this column represent the amount of compensation accrued
for each NEO during the fiscal year under FAS 123R. The amounts
do not represent the grant date fair value of equity compensation granted
in fiscal year 2007. The grant date fair value of the awards
granted in 2007 is shown in the Grant of Plan Based Awards For Fiscal
Year 2007 table and were determined using the Black Scholes option pricing
model with assumptions disclosed in our Annual Report on Form 10K for
the year ended December 31, 2007.
|
(3)
|
Includes
the amount of matching contribution under our 401(k) Plan and
reimbursement of premiums for enhanced life and disability insurance that
we made to or on behalf of our named executive
officers.
|
(4)
|
Dr.
Maddon received no bonus for the 2007 fiscal year. The amounts
reflect compensation expense associated with the vesting of Dr. Maddon’s
bonuses paid in 2005 and 2006. Specifically, on February 20,
2007, the Compensation Committee approved an award for Dr. Maddon
comprised of 15,597 shares of restricted common stock with a fair value at
the time of grant of $481,263, of which $368,007 was recognized as
compensation expense in our financial statements during
2007. The remainder of the award will be recognized as
compensation expense in 2008 as the restrictions
lapse. Similarly, in March of 2006, the Committee approved an
award of 18,080 shares with a fair value at the time of grant
of $524,862, of which, $401,577 became vested in the 2006 fiscal
year. The remainder of the award became vested in the 2007
fiscal year and is reported in the 2007 bonus column (See the Grants of
Plan-Based Awards for Fiscal Year 2006 table (contained in our Proxy
Statement for the 2006 fiscal year) and the Grants of Plan-Based Awards
for Fiscal Year 2007 table
(below)).
|
(5)
|
Amount
includes for each executive except Dr. Maddon (see footnote 4 above), a
performance-based discretionary bonus approved by the Committee in the
corresponding fiscal year (See our CD&A above for a detailed
description of these bonuses). Because these awards are not part of a
specific compensation plan, these are not shown in the Grant of Plan Based
Awards For Fiscal Year 2007 table.
|
(6)
|
Includes
$110,000 in cash paid in May 2007 to Dr. Boyd and Dr. Kremer upon
acceptance by the FDA of the filing of the Company’s NDA with
the FDA (See our CD&A above under the heading “Long Term
Incentives”).
|
Name
|
Grant
Date
|
Estimated
Future Payouts Under Equity Incentive Plan Awards Target (#)
|
All
Other Stock Awards: Number of Shares of Stock or Units (#)
|
All
Other Option Awards: Number of Securities Underlying Options
(#)
|
Exercise
or Base Price of Option Awards ($/Share)
|
Grant
Date Fair Value of Stock and Option Awards ($)
|
Paul
J. Maddon, M.D., Ph.D.
|
2/20/07
|
15,9571
|
|
481,263
|
||
7/2/07
|
|
37,5002
|
825,375
|
|||
7/2/07
|
112,5003
|
22.01
|
1,963,800
|
|||
Robert
A. McKinney, CPA
|
7/2/07
|
13,3332
|
293,459
|
|||
7/2/07
|
10,0004
|
22.01
|
174,350
|
|||
Mark
R. Baker, J.D.
|
7/2/07
|
13,3332
|
293,459
|
|||
7/2/07
|
10,0004
|
22.01
|
174,350
|
|||
Thomas
A. Boyd, Ph.D.
|
7/2/07
|
9,3332
|
205,419
|
|||
7/2/07
|
7,0004
|
22.01
|
122,045
|
|||
Alton
B. Kremer, M.D., Ph.D.
|
7/2/07
|
13,3332
|
293,459
|
|||
7/2/07
|
10,0004
|
22.01
|
174,350
|
(1)
|
Restricted
stock award vested 75% through 12/31/07 and the remaining 25% will vest on
6/20/08.
|
(2)
|
Restricted
stock awards vest 25% per year, with vesting dates of 6/20/08, 6/20/09,
6/20/10 and 6/20/11.
|
(3)
|
The
performance-based stock options vested at 40% through
12/31/07. The remaining 60% of the options are subject to
acceleration of vesting of a defined percentage of the award upon
achievement of defined milestones.
|
(4)
|
Stock
options vest 25% per year with vesting dates of 7/2/08, 7/2/09, 7/2/10 and
7/2/11.
|
Option
Awards
|
Stock
Awards
|
||||||||
Name
|
Number
of
Securities
Underlying Unexercised Options
(#)
Exercisable
|
Number
of Securities Underlying Unexercised Options
(#)
Unexercisable
|
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options
(#)
|
Option
Exercise Price
($)
|
Option
Expiration Date
|
Number
of Shares or Units of Stock That Have Not Vested
(#)
|
Market
Value of Shares or Units of Stock That Have Not Vested13
($)
|
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights
That Have Not Vested
(#)
|
Equity
Incentive Plan Payout Value of Unearned Shares, Units or Other Rights That
Have Not Vested
($)
|
Paul
J. Maddon,
|
45,000
|
67,5002
|
22.01
|
7/2/2017
|
|||||
M.D.,
Ph.D.
|
225,000
|
12.00
|
12/22/2008
|
||||||
112,500
|
15.06
|
7/1/2013
|
|||||||
112,500
|
15.06
|
7/1/2013
|
|||||||
75,000
|
12.29
|
7/1/2012
|
|||||||
0
|
33,0003
|
12.29
|
7/1/2012
|
96,491
|
1,743,592
|
–
|
–
|
||
275,001
|
12.00
|
12/22/2008
|
|||||||
30,000
|
7,5004
|
16.85
|
7/1/2014
|
||||||
28,125
|
9,3751
|
|
16.85
|
7/1/2014
|
|||||
75,000
|
21.39
|
7/1/2015
|
|||||||
72,500
|
72,5005
|
24.26
|
7/3/2016
|
||||||
Robert
A. McKinney,
|
6,250
|
6,2506
|
21.39
|
7/1/2015
|
|||||
CPA
|
25,000
|
13.75
|
4/16/2009
|
||||||
25,000
|
13.63
|
6/28/2010
|
|||||||
25,000
|
17.19
|
1/7/2010
|
|||||||
25,000
|
–
|
12.29
|
7/1/2012
|
23,458
|
423,886
|
–
|
–
|
||
25,000
|
15.06
|
7/1/2013
|
|||||||
12,500
|
12,5007
|
22.68
|
3/1/2015
|
||||||
6,250
|
18,7508
|
24.26
|
7/3/2016
|
||||||
0
|
10,0009
|
22.01
|
7/1/2017
|
||||||
Mark
R. Baker, J.D.
|
20,000
|
30,00010
|
20.02
|
6/20/2015
|
|||||
15,000
|
45,00011
|
–
|
27.71
|
2/21/2016
|
19,333
|
349,347
|
–
|
–
|
|
6,250
|
18,7508
|
24.26
|
7/3/2016
|
||||||
0
|
10,0009
|
22.01
|
7/2/2017
|
||||||
Thomas
A. Boyd,
|
12,500
|
12,5006
|
21.39
|
7/1/2015
|
|||||
Ph.D.
|
4,375
|
13,1258
|
24.26
|
7/3/2016
|
|||||
0
|
7,0009
|
–
|
22.01
|
7/2/2017
|
19,833
|
321,232
|
5,000
|
90,350
|
|
6,250
|
18,75011
|
27.71
|
2/21/2016
|
||||||
50,000
|
18.47
|
1/1/2012
|
|||||||
25,000
|
15.06
|
7/1/2013
|
|||||||
20,000
|
12.29
|
7/1/2012
|
|||||||
Alton
B. Kremer,
|
5,000
|
5,0006
|
21.39
|
7/1/2015
|
|||||
M.D.,
Ph.D.
|
0
|
10,0009
|
22.01
|
7/2/2017
|
|||||
4,375
|
13,1258
|
–
|
24.26
|
7/3/2016
|
19,958
|
323,191
|
5,000
|
90,350
|
|
6,250
|
18,75011
|
27.71
|
2/21/2016
|
||||||
16,000
|
16,00012
|
13.57
|
9/28/2014
|
(1)
|
Stock
options vest 25% on each anniversary of the grant with the remaining
vesting on of 6/30/08.
|
(2)
|
Performance
stock options vested at 40% through 12/31/07. The remaining 60%
of the options are subject to acceleration of vesting of a defined
percentage of the award upon achievement of defined
milestones. (See our CD&A above under the heading “Long-Term Incentives”
for a discussion of the performance
criteria).
|
(3)
|
Performance
options cliff vest on 6/30/11, with acceleration of vesting of defined
percentages of the award upon achievement of defined
milestones.
|
(4)
|
Performance
options vested 80% through 2007 due to the achievement of specified
milestones. The remaining 20% will cliff vest on 6/1/14 unless
accelerated upon achievement of defined
milestones.
|
(5)
|
Performance
options vested at 50% with the balance subject to acceleration of vesting
of a defined percentage of the award upon achievement of defined
milestones.
|
(6)
|
Stock
options vested 50% through 12/31/07 with the remaining vesting on of
7/1/08 and 7/1/09.
|
(7)
|
Stock
options vested 50% through 12/31/07 with the remaining vesting on of
3/1/08 and 3/1/09.
|
(8)
|
Stock
options vested 25% through 12/31/07 with the remaining vesting on of
7/3/08, 7/3/09 and 7/3/10.
|
(9)
|
Stock
options vested 25% through 12/31/07 with the remaining vesting on of
7/2/08, 7/2/09, 7/2/10 and 7/3/11.
|
(10)
|
Stock
options vested 40% through 12/31/07 with the remaining vesting on of
6/20/08, 6/20/09 and 6/20/10.
|
(11)
|
Stock
options vested 25% through 12/31/07 with the remaining vesting on of
2/21/08, 2/21/09 and 2/21/10.
|
(12)
|
Stock
options vested 60% through 12/31/07 with the remaining vesting on of
9/28/08 and 9/28/09.
|
(13)
Based on the closing price of our common stock on 12/31/07 of
$18.07.
|
Option
Awards
|
Stock
Awards
|
|||
Name
|
Number
of Shares Acquired on Exercise
(#)
|
Value
Realized on Exercise
($)
|
Number
of Shares Acquired on Vesting
(#)
|
Value
Realized on Vesting
($)
|
Paul
J. Maddon, M.D., Ph.D.
|
231,000
|
4,402,146
|
41,072
|
943,473
|
Robert
A. McKinney, CPA
|
16,000
|
390,648
|
5,000
|
113,000
|
Mark
R. Baker, J.D.
|
-
|
-
|
2,000
|
45,200
|
Thomas
A. Boyd, Ph.D.
|
16,000
|
135,272
|
5,375
|
121,475
|
Alton
B. Kremer, M.D., Ph.D.
|
-
|
-
|
2,500
|
56,500
|
Name1
|
Fees
Earned or Paid in Cash
($)
|
Option
Awards2
($)
|
All
Other Compensation3
($)
|
Total
($)
|
Kurt
W. Briner
|
40,000
|
653,813
|
-
|
693,813
|
Paul
F. Jacobson
|
42,500
|
653,813
|
-
|
696,313
|
Charles
A. Baker
|
17,500
|
174,350
|
-
|
191,850
|
Mark
F. Dalton
|
17,500
|
174,350
|
-
|
191,850
|
Stephen
P. Goff, Ph.D.
|
15,000
|
174,350
|
30,000
|
219,350
|
David
A. Scheinberg, M.D., Ph.D.
|
15,000
|
174,350
|
199,334
|
388,684
|
Nicole
Williams
|
22,500
|
281,611
|
-
|
304,111
|
·
|
$2,000
for each meeting of the Board attended in person, $1,000 for each
in-person meeting attended by telephone and $500 for participation in each
telephonic meeting;
|
·
|
for
committee meetings held other than in conjunction with a meeting of the
entire Board, $1,000 for attendance in person and $500 for telephonic
participation;
|
·
|
for
committee meetings held on the day after a meeting of the entire Board,
$500 for participation;
|
·
|
for
committee meetings held on the same day, no additional compensation is
paid;
|
·
|
an
annual retainer fee of $15,000, except for Messrs. Briner and Jacobson who
are entitled to an annual retainer fee of $40,000 as described above;
and
|
·
|
an
option to purchase 10,000 fully-vested shares of our common stock granted
annually on the first business day of July with an exercise price equal to
the fair market value as of the date of
grant.
|
·
|
In-the-money
Original Options cancelled: 10,000
|
·
|
New
Restricted Shares: 4,643
|
·
|
Tax
Shares issued related to tax obligation:
1,858
|
·
|
Fair
market value New Options issued:
5,357
|
Cash
Severance
|
Equity
|
Benefits
Continuation6
($)
|
Gross
up of I.R.C. Golden Parachute Excise Tax Resulting from
Change-in-Control
($)
|
Total
($)
|
|||||
Base
Salary
|
Bonus7
|
Value
of Vested Equity
($)
|
Value
of Accelerated Unvested Equity5
($)
|
||||||
Circumstances
of Termination1:
|
Multiple
|
($)
|
Multiple
|
($)
|
|||||
Termination
by us for cause or voluntary termination, normal retirement by named
executive officer in the normal course of business
|
N/A
|
N/A
|
N/A
|
N/A
|
4,216,669
|
N/A
|
N/A
|
N/A
|
4,216,669
|
Death
or disability of named executive officer in the normal course of
business2
|
1.0
|
600,000
|
N/A
|
735,416
|
4,216,669
|
N/A
|
25,182
|
N/A
|
5,577,267
|
Termination
by us without cause or by the named executive officer with good
reason3
|
2.0
|
1,200,000
|
2.0
|
1,120,833
|
4,216,669
|
1,954,920
|
25,182
|
N/A
|
8,517,604
|
Termination
by us without cause or by the named executive officer with good reason
following a change in control4
|
3.0
|
1,800,000
|
3.0
|
1,506,250
|
4,216,669
|
1,954,920
|
37,773
|
N/A
|
9,515,612
|
(1)
|
Assumes
that the triggering event occurred on December 31, 2007, on which date the
closing price per share of our common stock was
$18.07.
|
(2)
|
Dr.
Maddon receives a pro-rated amount of bonus from the beginning of the year
of termination to the date of termination. In addition, he
receives one times his base salary for the year of termination and average
bonus (calculated using the average of the annual bonuses paid to him in
the three years preceding the year of termination). For
purposes of this calculation, his bonus used to calculate pro-rated bonus
is considered to be $350,000.
|
(3)
|
Dr.
Maddon receives cash severance equal to twice his base salary for the year
of termination and twice the average of the annual bonuses paid to him in
the three years preceding the year of termination and, in addition, a
pro−rated amount of bonus from the beginning of the year of termination to
the date of termination. For purposes of this calculation, base
salary is $600,000, his bonuses for the three years preceding 2007 are
$150,000, $525,000 and $481,250 and his bonus for 2007 is
$0. His target bonus for purposes of determining his pro-rated
bonus is $350,000 (See our CD&A for a discussion of Dr. Maddon’s 2007
bonus).
|
(4)
|
Dr.
Maddon receives cash severance equal to three times his base salary for
the year of termination and three times the average of the annual bonuses
paid to him in the three years preceding the year of termination and, in
addition, a pro−rated amount of bonus from the beginning of the year of
termination to the date of termination. For purposes of this
calculation, base salary is $600,000, his bonuses for the three years
preceding 2007 are $150,000, $525,000 and $481,250 and his bonus for 2007
is $0. His target bonus for purposes of determining his
pro-rated bonus is $350,000 (See our CD&A for a discussion of Dr.
Maddon’s 2007 bonus).
|
(5)
|
Assumes
acceleration of vesting at December 31, 2007 of all unexercisable and
unearned stock options, totaling 189,875 options, as set forth in the
Outstanding Equity Awards at Fiscal Year-End table above and
the sale of the resulting common stock on that date. The
proceeds to Dr. Maddon, before taxes, are $211,328, calculated as the
product of (i) the difference between the closing price of our common
stock on December 31, 2007 of $18.07 and the exercise price of each
accelerated stock option and (ii) the respective number of options for
which vesting was accelerated. The amount presented above also
assumes acceleration of vesting of all outstanding shares of restricted
stock, totaling 96,491 shares, at December 31, 2007 and the sale of the
stock on that date. The proceeds to Dr. Maddon, before taxes,
are $1,743,592, calculated as the product of the number of shares of
restricted stock outstanding and the closing price of our common stock on
December 31, 2007 of $18.07.
|
(6)
|
Dr.
Maddon's health and welfare benefits will continue for 24 or 36
months. The benefits cost includes the employer cost of health,
dental, disability and group life
insurance.
|
(7)
|
The
bonus column includes the bonus multiple calculated using the multiple
shown plus a pro-rated bonus of $350,000 where any amount is
shown.
|
|
–
|
Termination
prior to a Change-in-Control (defined
below).
|
·
|
If
terminated by us for Cause (defined below) or if he resigns without Good
Reason (defined below), Dr. Maddon will be entitled to a pro-rated salary
through his termination date and his unvested equity compensation will be
forfeited.
|
·
|
If
terminated due to death or disability, Dr. Maddon or his estate will be
paid Dr. Maddon’s salary and a pro-rated bonus until his termination
date. He or his estate will also be entitled to continued
welfare benefits for a period of two years and a lump sum payment equal to
the sum of his base salary and Average Bonus (defined as the average of
the bonuses paid to him in the three years preceding the year of
termination). All time-based unvested equity will vest and all
milestone-based unvested equity will vest if the milestones are achieved
under the original vesting provisions.
|
·
|
If
terminated without cause by us or if Dr. Maddon resigns for Good Reason,
Dr. Maddon will be entitled to a pro-rated salary through his termination
date. In addition, we will pay him a lump sum equal to twice
his base salary and Average Bonus, continue his welfare benefits for two
years and all time-based and performance-based equity will vest
immediately.
|
|
–
|
Termination
within two year after or three months prior to a Change-in-Control of the
Company.
|
·
|
If
terminated by us for Cause or he resigns without Good Reason (defined
below), Dr. Maddon will be entitled to a pro-rated salary through his
termination date and his unvested equity compensation will be
forfeited.
|
·
|
If
terminated due to death or disability, Dr. Maddon or his estate will be
paid Dr. Maddon’s salary and a pro-rated bonus until his termination
date. He or his estate will also be entitled to continued
welfare benefits for a period of two years and a lump sum payment equal to
the sum of his base salary and Average Bonus. All time-based
unvested equity will vest and all milestone-based unvested equity will
vest if the milestones are achieved under the original vesting
provisions.
|
·
|
If
terminated without cause or if he resigns for Good Reason during the
designated period before or after a Change-in-Control, Dr. Maddon will be
entitled to three times his base salary and Average Bonus and continuation
of welfare benefits for three years. All of his time-based and
performance-based equity will become immediately vested upon
termination. The Company will also pay Dr. Maddon a gross-up
for any excise tax incurred under sections 280G or 4999 of the Internal
Revenue Code. The gross-up will not be paid if reducing his
cash severance by 10% will result in no tax being
incurred.
|
Shares
Beneficially Owned2
|
||
Name and Address of Beneficial Owner1
|
Number23
|
Percent
|
Entities
affiliated with Tudor Investment Corporation3
1275
King Street
Greenwich,
CT 06831
|
2,342,388
|
7.8%
|
Paul
Tudor Jones II4
1275
King Street
Greenwich,
CT 06831
|
2,888,513
|
9.7%
|
Delaware
Management Holdings5
One
Commerce Square, 2005 Market Street
Philadelphia,
PA 19103
|
614,343
|
2.1%
|
Barclays
Global Investors, NA.6
45
Fremont Street
San
Francisco, CA 94105
|
1,137,907
|
3.8%
|
Federated
Investors, Inc.7
Federated
Investors Tower
Pittsburgh,
PA 15222
|
2,494,906
|
8.3%
|
Sectoral
Asset Management Inc.8
2120-1000
Sherbrooke Street
West
Montreal, PQ H3A 3G4 Canada
|
3,442,906
|
11.5%
|
Wellington
Management Company9
75
State Street
Boston,
MA 02109
|
3,701,781
|
12.4%
|
Paul
J. Maddon, M.D., Ph.D.10
|
1,745,774
|
5.6%
|
Charles
A. Baker11
|
103,981
|
*
|
Kurt
W. Briner12
|
195,500
|
*
|
Mark
F. Dalton13
|
2,514,888
|
8.4%
|
Stephen
P. Goff, Ph.D.14
|
151,000
|
*
|
Paul
F. Jacobson15
|
330,600
|
1.1%
|
David
A. Scheinberg, M.D., Ph.D.16
|
157,789
|
*
|
Nicole
S. Williams17
|
15,000
|
*
|
Robert
A. McKinney, CPA18
|
189,821
|
*
|
Thomas
A. Boyd, Ph.D.19
|
160,939
|
*
|
Alton
B. Kremer, M.D., Ph.D.20
|
67,725
|
*
|
Mark
R. Baker, J.D.21
|
81,270
|
*
|
All
directors and executive officers as a group22
|
6,123,033
|
18.9%
|
(1)
|
Unless
otherwise specified, the address of each beneficial owner is c/o Progenics
Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York
10591.
|
(2)
|
Except
as indicated and pursuant to applicable community property laws, each
stockholder possesses sole voting and investment power with respect to the
shares of common stock listed. The number of shares of common
stock beneficially owned includes the shares issuable pursuant to stock
options to the extent indicated in the footnotes in this
table. Shares issuable upon exercise of these options are
deemed outstanding for computing the percentage of beneficial ownership of
the person holding the options but are not deemed outstanding for
computing the percentage of beneficial ownership of any other
person.
|
(3)
|
The
number of shares owned by entities affiliated with Tudor Investment
Corporation (TIC) consists of 1,820,068 shares held of record by The Tudor
BVI Portfolio L.P., a limited partnership organized under the law of the
Cayman Islands (Tudor BVI), 2,107,881 shares held of record by TIC,
193,126 shares held of record by Tudor Arbitrage Partners L.P. (TAP),
25,981 shares held of record by Tudor Proprietary Trading, L.L.C. (TPT),
and 208,526 shares held of record by Tudor Global Trading LLC (TGT). In
addition, because TIC provides investment advisory services to Tudor BVI,
it may be deemed to beneficially own the shares held by such
entity. TIC disclaims beneficial ownership of such
shares. TGT is the general partner of TAP. Tudor
Group Holdings LLC (TGH) is the sole member of TGT and indirectly holds
all of the membership interests of TPT. TGH is also the sole
limited partner of TAP. TGH expressly disclaims beneficial
ownership of the shares beneficially owned by each of such
entities. TGT disclaims beneficial ownership of shares held by
TAP. The number set forth does not include shares owned of
record by Mr. Jones and Mr. Dalton. See Notes (4) and
(13).
|
(4)
|
Includes
2,888,513 shares beneficially owned by entities affiliated with
TIC. Mr. Jones is the Chairman and indirect principal
equity owner of TIC, TPT and TGT, and the indirect principal equity owner
of TAP. Mr. Jones may be deemed to be the beneficial owner of
shares beneficially owned, or deemed beneficially owned, by entities
affiliated with TIC. Mr. Jones disclaims beneficial
ownership of such shares. See
Note (3).
|
(5)
|
Based
on a Schedule 13G filed on February 7, 2008, the number of shares owned by
Delaware Management Holdings and Delaware Management Business Trust
consists of 614,343 shares held by Delaware Management Holdings and
Delaware Management Business Trust, which share voting and dispositive
powers.
|
(6)
|
Based
on a Schedule 13G, filed on January 30, 2008, the number of shares owned
by Barclays Global Investors, NA. and Barclays Global Fund Advisors is
1,137,907, which share voting and dispositive
power.
|
(7)
|
Based
on a Schedule 13G, filed February 12, 2008, Federated Investors, Inc. (the
“Parent”) is the parent holding company of Federated Equity Management
Company of Pennsylvania and Federated Global Investment Management
Corp. All of the Parent’s outstanding voting stock is held in
the Voting Shares Irrevocable Trust for which John F. Donahue, Rhodora J.
Donahue and J. Christopher Donahue act as trustees and they have the
collective voting control over the
Parent.
|
(8)
|
Sectoral
Asset Management Inc. in its capacity as an investment adviser has the
sole right to vote or dispose of the 3,442,906 shares set forth in
Schedule 13G filed on February 11, 2008. Jerome G. Pfund and
Michael L. Sjostrom are the sole shareholders of Sectoral Asset Management
Inc.
|
(9)
|
Based
on a Schedule 13G, filed on February 14, 2008, the number of shares owned
by Wellington Management Company, LLP is 3,701,781 of shared dispositive
power.
|
(10)
|
Includes
598,657 shares outstanding; 1,050,626 shares issuable upon exercise of
options exercisable within 60 days of March 31, 2008 and 96,491 shares of
restricted stock. Also includes 1,000 shares held by Dr.
Maddon’s spouse, the beneficial ownership of which Dr. Maddon
disclaims. Excludes 49,274 shares held by a trust, of which his
spouse is the beneficiary; neither Dr. Maddon nor his spouse has
investment control over such trust.
|
(11)
|
Includes
21,481 shares owned by the Baker Family Limited Partnership and 82,500
shares issuable upon exercise of options held by Mr. Baker and exercisable
within 60 days of March 31, 2008.
|
(12)
|
Includes
3,000 shares outstanding and 192,500 shares issuable upon exercise of
options held by Mr. Briner exercisable within 60 days of March 31,
2008.
|
(13)
|
Includes
71,000 shares held of record directly by Mr. Dalton, 85,000 shares
issuable upon exercise of options held by Mr. Dalton exercisable
within 60 days of March 31, 2008 and 16,500 shares held of record by DF
Partners, a family partnership of which Mr. Dalton is the sole
general partner. The number set forth also includes 2,342,388
shares beneficially owned by entities affiliated with TIC. Mr.
Dalton is Vice Chairman and President and an equity owner of TIC and
TGH. Mr. Dalton is also the Vice Chairman and President and an
indirect equity owner of TGT and TPT. Mr. Dalton disclaims
beneficial ownership of shares beneficially owned, or deemed beneficially
owned, by entities affiliated with TIC and DF Partners, except to the
extent of his pecuniary interest therein. See Note
(3).
|
(14)
|
Includes
33,500 shares outstanding and 117,500 shares issuable upon exercise of
options held by Dr. Goff exercisable within 60 days of March 31,
2008.
|
(15)
|
Includes
188,100 shares outstanding and 142,500 shares issuable upon exercise of
options held by Mr. Jacobson exercisable within 60 days of March 31,
2008.
|
(16)
|
Includes
39,681 shares outstanding and 111,607 shares issuable upon exercise of
options held by Dr. Scheinberg exercisable within 60 days of March 31,
2008 and 6,501 shares of restricted
stock.
|
(17)
|
Includes
15,000 shares issuable upon exercise of options exercisable within 60 days
of March 31, 2008.
|
(18)
|
Includes
10,113 shares outstanding and 156,250 shares issuable upon exercise of
options held by Mr. McKinney exercisable within 60 days of March 31,
2008. Also includes 23,458 shares of restricted
stock.
|
(19)
|
Includes
11,731 shares outstanding and 124,375 shares issuable upon exercise of
options held by Dr. Boyd exercisable within 60 days of March 31,
2008. Also includes 24,833 shares of restricted
stock.
|
Includes
4,892 shares outstanding and 37,875 shares issuable upon exercise of
options held by Dr. Kremer exercisable within 60 days of March 31,
2008. Also includes 24,958 shares of restricted
stock.
|
(21)
|
Includes
5,687 shares outstanding and 56,250 shares issuable upon exercise of
options held by Mr. Baker exercisable within 60 days of March 31,
2008. Also includes 19,333 shares of restricted
stock.
|
(22)
|
Includes
3,379,310 shares outstanding, 231,740 shares of restricted stock and
2,511,983 shares issuable upon the exercise of stock options exercisable
within 60 days of March 31, 2008 held by Directors and Named Executive
Officers as set forth in the above table and by all other executive
officers.
|
(23)
|
None
of the shares held by beneficial owners and management are pledged as
collateral.
|
|
Audit
Committee
|
|
Compensation
Committee
|
|
Nominating and
Corporate Governance
Committee
|
·
|
Each
candidate shall be prepared to represent the best interests of all of our
stockholders and not just one particular
constituency.
|
·
|
Each
candidate shall be an individual who has demonstrated integrity and ethics
in his or her personal and professional life and has established a record
of professional accomplishment in his or her chosen
field.
|
·
|
No
candidate, or family member (as defined in the Nasdaq Marketplace rules)
or affiliate or associate (each as defined in Rule 405 under the
Securities Act of 1933, as amended) of a candidate, shall have any
material personal, financial or professional interest in any of our
present or potential competitors.
|
·
|
Each
candidate shall be prepared to participate fully in Board activities,
including, if eligible, active membership on at least one Board committee
and attendance at, and active participation in, meetings of the Board and
any committee of which he or she is a member, and not have other personal
or professional commitments that would, in the Nominating and Corporate
Governance Committee’s sole judgment, interfere with or limit his or her
ability to do so.
|
·
|
Each
candidate should contribute to the Board’s overall diversity — diversity
being broadly construed to mean a variety of opinions, perspectives,
personal and professional experiences and backgrounds, as well as other
differentiating characteristics.
|
·
|
Each
candidate should contribute positively to the collaborative culture among
Board members.
|
·
|
Each
candidate should possess professional and personal experiences and
expertise relevant to our goal of being a leading biopharmaceutical
company. At this stage of our development, relevant experiences
might include, among other things, large biotechnology or pharmaceutical
company CEO or senior management experience, senior-level management
experience in medical research or clinical development activities in the
fields of oncology, virology, immunology or molecular biology within a
public company or large university setting, and relevant senior-level
expertise in one or more of the following areas: finance, accounting,
sales and marketing, organizational development and public
relations.
|
VOTE BY INTERNET - www.proxyvote.com
Use the Internet to
transmit your voting instructions and for electronic delivery of
information up
until
11:59 P.M. Eastern Time on June 1, 2008. Have your proxy card
in hand when you access the
web site
and follow the instructions to obtain your records and to create an
electronic voting
instruction
form.
VOTE BY
PHONE-1-800-690-6903
Use
any touch-tone telephone to transmit your voting instructions up until
11:59 P.M. Eastern Time
on June
1, 2008. Have your proxy card in hand when you call and then
follow the instructions.
VOTE
BY MAIL
Mark,
sign and date your proxy card and return it in the postage-paid envelope
we’ve provided or
return to
Progenics Pharmaceuticals, Inc., c/o Broadridge Financial Solutions, Inc.,
51 Mercedes Way,
Edgewood,
NY 11717
VOTE
IN PERSON
Attend the Annual
Shareholders Meeting at 10:00 A.M. Eastern Time on Monday, June 2,
2008
Landmark at Eastview
Rockland Room
777
Old Saw Mill River Road
Tarrytown, NY 10591
ELECTRONIC DELIVERY OF FUTURE SHAREHOLDER COMMUNICATIONS
If you would like to
reduce the costs incurred by Progenics Pharmaceuticals, Inc. in mailing
proxy
materials,
you can consent to receiving all future proxy statements, proxy cards and
annual reports
electronically
via e-mail or the Internet. To sign up for electronic delivery,
please follow the
instructions
above to vote using the Internet and, when prompted, indicate that you
agree to receive
or access
shareholder communications electronically in future
years.
|
1. ELECTION
OF DIRECTORS:
|
||||||||||
NOMINEES:
|
||||||||||
01)
Kurt W. Briner
|
||||||||||
02)
Paul F. Jacobson
|
For
All
o
|
Withhold
All
o
|
For
All Except
o
|
To
withhold authority to vote for any individual nominee(s),
mark “For All Except” and write the nominee’s number on the
line below.
|
||||||
03)
Charles A. Baker
|
||||||||||
04)
Mark F. Dalton
|
||||||||||
05)
Stephen P. Goff, Ph.D.
|
||||||||||
06)
Paul J. Maddon, M.D., Ph.D.
|
||||||||||
07)
David A. Scheinberg, M.D., Ph.D.
|
||||||||||
08)
Nicole S. Williams
|
||||||||||
Vote
On Proposals
|
2. Approval
of amendments to the Company’s 1998 Employee Stock Purchase Plan and 1998
Non-Qualified Employee Stock Purchase Plan to increase the number of
shares of common stock reserved for issuance thereunder to 2,400,000 and
600,000, respectively.
|
For
o
|
Against
o
|
Abstain
o
|
|||
3.
Ratification of the selection of PricewaterhouseCoopers LLP to serve as
the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2008.
|
o
|
o
|
o
|
|||
4.
Authority to vote in their discretion on such other business as may
properly come before the meeting.
|
o
|
o
|
o
|
|||
NOTE:
Please sign exactly as your name or names appear (s) on this
Proxy. When shares are held jointly, each holder should
sign. When signing as executor, administrator, attorney,
trustee or guardian, please give full title as such. If the
signer is a corporation, please sign full corporate name by duly
authorized officer, giving full title as such. If signer is a
partnership, please sign in partnership name by authorized
person.
|
||||||
For address change and/or comments, please check this box and write them
on the
back where indicated
|
o | |||||
Please indicate whether you plan to attend this meeting
|
Yes
|
No
|
||||
Signature (PLEASE SIGN WITHIN
BOX)
Date
|
Signature
(Joint Owners)
|
Date
|